https://academic.oup.com/humupd/advance-article-abstract/doi/10.1093/humupd/dmz005/5365598?redirectedFrom=fulltext
https://www.ncbi.nlm.nih.gov/pubmed/30809650
New synthetic ligands, targeting PGR, retinoic acid receptors and ESR2, may offer novel treatment options.
